Natera (NASDAQ:NTRA) Insider John Fesko Sells 898 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 898 shares of the stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total value of $382,853.32. Following the transaction, the insider directly owned 195,578 shares of the company’s stock, valued at approximately $83,382,724.52. The trade was a 0.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $317,086.00.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The stock was sold at an average price of $321.53, for a total value of $2,095,411.01.
• On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The shares were sold at an average price of $267.99, for a total value of $79,057.05.

Natera Trading Up 2.7%

Shares of NTRA stock traded up $11.58 on Thursday, reaching $436.00. The company’s stock had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. The stock’s fifty day simple moving average is $375.27 and its 200-day simple moving average is $265.54. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.74) earnings per share. Sell-side analysts anticipate that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NTRA shares. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Wells Fargo & Company lifted their price target on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Rothschild & Co Redburn started coverage on Natera in a research note on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada raised their price objective on Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $394.31.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Natera during the second quarter valued at approximately $2,962,770,000. Bank of America Corp DE bought a new stake in shares of Natera during the 2nd quarter worth approximately $199,960,000. Legal & General Group Plc bought a new stake in shares of Natera during the 2nd quarter worth approximately $150,143,000. Bank of New York Mellon Corp purchased a new position in Natera during the 2nd quarter valued at $149,278,000. Finally, Avala Global LP purchased a new position in Natera during the 2nd quarter valued at $124,867,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.